Clinical Trial Update: Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pembrolizumab in combination with carboplatin for recurrent ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• Paraplatin (Carboplatin)

Snippet

Sponsor: University of Washington | Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING